Kairos Pharma (KAPA) announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for ...

Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology industries, surprising investors with a $100 million revenue shortfall that led ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $175.00. The company’s shares closed ...

For big pharma companies, blockbuster drugs can feel like a double-edged sword. Their discovery brings huge excitement and share price gains in anticipation of the cash that will soon roll in.

Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent ...

India's pharmaceutical sector is witnessing remarkable growth, almost achieving its export target before FY25. Drug formulations and biologicals lead the exports, supported by significant growth in ...

The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery. Early adopters are seeing ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,01,091.27 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...

A Ugandan doctor vaccinates the contact of a patient who tested positive during the launch of the vaccination for the Sudan strain of the Ebola virus with a trial vaccine at the Mulago Guest House ...

Hueco Tanks is a series of rock outcrops that are thousands of years old. The area provided previous residents with food, shelter and places to farm. Today, visitors tour the site primarily to ...